Previous close | 125.85 |
Open | 127.24 |
Bid | 125.03 x 800 |
Ask | 125.59 x 800 |
Day's range | 125.05 - 128.70 |
52-week range | 99.14 - 134.63 |
Volume | |
Avg. volume | 8,233,711 |
Market cap | 317.26B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 139.18 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.08 (2.46%) |
Ex-dividend date | 16 Sept 2024 |
1y target est | N/A |
On Tuesday, Merck & Co Inc (NYSE:MRK) shared topline results from its Phase 2b/3 clinical trial (MK-1654-004) of clesrovimab (MK-1654). Clesrovimab is the company’s investigational prophylactic monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease. Clesrovimab met its primary safety and efficacy endpoints in the trial, including reducing medically attended lower respiratory infections (MALRI) caused by RSV through Day 150. Participants were randomized to
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.
Key Insights Significantly high institutional ownership implies Merck's stock price is sensitive to their trading...